pocketful logo light
pocketful logo light
Cipla Ltd logo

Cipla Ltd

NSE: CIPLA BSE: 500087

1376.50

(0.82%)

Fri, 19 Jun 2026, 02:23 am

Cipla Share Price Live Chart

1 Day

(0.82%)

No Result Found

Summary

  • Market Cap (in Cr)

    112970.91

  • Net Profit (in Cr)

    5291.05

  • P/B

    3.73

  • Sector P/E

    33.76

  • P/E

    22.08

  • EV/EBITDA

    14.53

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    18.28

  • ROCE

    23.15

  • Debt/Equity

    0.02

  • EPS (TTM)

    50.50

  • Dividend Yield

    0.93

  • Book Value

    426.24

  • Interest Cover

    111

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters29.2129.2129.2129.1929.20
FII22.5523.9324.5425.2426.28
DII31.9730.7230.2529.2628.15
Public16.2616.1315.9916.3016.37
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

44.66

MACD

3.23

50 DMA

1337.49

200 DMA

1424.25

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1713.001543.201472.101373.401302.301203.601033.80
Fibonacci1543.201478.341438.261373.401308.541268.461203.60
Camarilla1447.691432.131416.571373.401385.431369.871354.31

Pivots Level: Classic

R3

+339.60

1713.00

R2

+169.80

1543.20

R1

+98.70

1472.10

1373.40
1373.40
Pivot Point
LTP: 1355.50

S1

-71.10

1302.30

S2

-169.80

1203.60

S3

-339.60

1033.80

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1373.83

  • 20-EMA

    1376.10

  • 30-EMA

    1369.28

  • 50-EMA

    1356.86

  • 100-EMA

    1360.66

  • 200-EMA

    1395.54

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
13 May 2026board-meetingsAccounts, Quarterly Results, Final Dividend
13 May 2026agm
13 May 2026dividend₹13.00 Dividend /Share05 Jun 2026
23 Jan 2026board-meetingsQuarterly Results
30 Oct 2025board-meetingsQuarterly Results
27 May 2025dividendFinal Dividend - Rs. - 1327 Jun 2025
13 May 2025agm
13 May 2025dividend₹13.00 Dividend /Share27 Jun 2025
02 Jul 2024dividendFinal Dividend - Rs. - 1302 Aug 2024
10 May 2024dividend₹13.00 Dividend /Share02 Aug 2024

Read More

Peer Comparison

Cipla Ltd logo

Cipla Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Zydus Lifesciences Ltd logo

Zydus Lifesciences Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Cipla Ltd About

Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1935

Headquarters

CEO

Y K Hamied

Employees

Contact

Website icon

Website

http://www.cipla.com

Email icon

Email

cosecretary@cipla.com, contactus@cipla.com

Phone icon

Phone

91-22-24826000

Location icon

Location

Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel, Mumbai, Maharashtra, 400013

Read More

Cipla Ltd Company History

YearHistory
2020
  • Completed phase-3 clinical study of generic asthma drug.
  • Inked licensing pact with Gilead Sciences for potential COVID-19 treatment drug.
  • Launched generic remdesivir for coronavirus patients.
  • Collaborated with Stempeutics to launch Stempeucel for CLI treatment in India.
  • Launched antibody detection kit for COVID-19 in India.
  • Conferred Golden Peacock Global Award for Excellence in Corporate Governance 2020.
2021
  • Set up 30 MW solar plant in Maharashtra.
  • Partnered with Alvotech to market biosimilars in Australia and New Zealand.
  • Bagged National Energy Conservation Award 2021 in drug and pharmaceutical sector.
  • Won Gold for Remdesivir in Covid Care Brand Category.
2022
  • Launched leuprolide acetate injection depot (22.5mg).
  • Received USFDA approval for generic Revlimid (Lenalidomide Capsules).
  • Launched child-friendly 4-in-1 antiretroviral treatment for HIV with DNDi in South Africa.
  • Scored highest among pharma companies in CRISIL Sustainability Rating 2022.
  • Won Frost & Sullivan and TERI Sustainability 4.0 Award.
2023
  • Acquired additional stake in GoApptiv Private Limited.
  • Announced acquisition of South Africa-based Actor Pharma.
2024
  • Acquired additional shares in Achira Labs Private Limited.
  • Merged Cipla Technologies LLC, USA with Cipla USA Inc.
  • Announced joint venture in the US with Kemwell Biopharma and Manipal Education & Medical Group for cell therapy products.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS (SINGAPORE) PTE.- ODIblockSell91604156516 Oct 2025
GOLDMAN SACHS BANK EUROPESE - ODIblockBuy91604156516 Oct 2025
THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828blockSell156532148514 Jul 2025
THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849blockBuy156532148514 Jul 2025
SAMINA HAMIEDbulkSell89547501518.7502 Dec 2024
RUMANA HAMIEDbulkSell49432501518.7502 Dec 2024
SAMINA HAMIEDbulkSell8954750134515 May 2024
ICICI PRUDENTIAL MUTUAL FUNDbulkBuy5525999134515 May 2024
SHIRIN HAMIEDbulkSell6363000134515 May 2024
RUMANA HAMIEDbulkSell4943250134515 May 2024

Read More

Cipla Ltd News

Cipla Expands Manufacturing for Respiratory & Specialty Products

Cipla is growing its manufacturing capabilities for respiratory and specialty products across India, China, and the U.S., signaling a broader production expansion strategy.

17 Jun 2026

companies

Cipla appoints Shivam Puri as CEO – One India Business

Cipla Limited has appointed Mr Shivam Puri as the Chief Executive Officer – One India Business effective July 1, 2026. The Board also granted him stock options and ESARs under employee benefit schemes.

16 Jun 2026

companies

USFDA Labels Cipla's Goa Facility as VAI

USFDA has classified Cipla's Goa facility inspection as Voluntary Action Indicated with observations, signaling no immediate regulatory action is required.

11 Jun 2026

companies

Cipla Eyes 10% Revenue From Innovations in 5 Years

Cipla states most of its core revenue will continue to come from generic drugs, while targeting 10% of total revenue from innovations over the next five years.

10 Jun 2026

companies

Cipla to host analyst meet on June 9

Cipla Limited will hold an in-person meeting with ICICI Securities on June 9, 2026, in Mumbai. The event is part of the ICICI Securities India Investor Conference.

02 Jun 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number